Yahoo Finance • 4 months ago
Key Insights Significantly high institutional ownership implies Nektar Therapeutics' stock price is sensitive to their trading actions The top 19 shareholders own 50% of the company Recent sales by insiders If you want to know who really... Full story
Yahoo Finance • 9 months ago
SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time. (... Full story
Yahoo Finance • 9 months ago
SAN FRANCISCO, Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial m... Full story
Yahoo Finance • 11 months ago
Key Insights Given the large stake in the stock by institutions, Nektar Therapeutics' stock price might be vulnerable to their trading decisions The top 11 shareholders own 51% of the company Recent sales by insiders If you want to know... Full story
Yahoo Finance • 2 years ago
NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) breached their fiduciary duties to... Full story
Yahoo Finance • 2 years ago
SAN FRANCISCO, July 26, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2022 on Thursday, August 4, 2022, after the close of U.S.-based financial markets. Howard Robin, Pre... Full story
Yahoo Finance • 3 years ago
In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts. You can skip our analysis of the pharmaceutical industry and go directly to Analysts Are Downgrading These 5 Pharmaceutical Stocks. The pharma... Full story